Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
To counter this limitation, a group of GLP-1 receptor agonists (GLP-1RAs), which are resistant to DPP4-mediated degradation [32], have been developed and shown to be effective in treating T2DM and obesity [33]
Can be a pain to swallow because of its size
[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)
A standard treatment plan starts with 0.25mg per week
US$ 26.81
US$ 20.32
US$ 25.81
US$ 29.54
